SCHEMBL2586844

SCHEMBL2586844

NC(=O)c1cccc2c1c1[c]cccc1n2Cc1c(Cl)cccc1Cl

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.45
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
XBP1 P17861 1/20 0.45
PLA2G2A P14555 6/20 0.40
CYP3A4 P08684 3/20 0.37
CYP2C9 P11712 2/20 0.37
CYP2C19 P33261 2/20 0.37
CYP1A2 P05177 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
ALDH1A1 P00352 3/20 0.37
HTT P42858 3/20 0.37
MAPK1 P28482 2/20 0.37
CRHBP P24387 1/20 0.37
CRHR2 Q13324 1/20 0.37
KDM4E B2RXH2 4/20 0.34
HPGD P15428 1/20 0.34
MAPK8 P45983 1/20 0.34
CCR2 P41597 1/20 0.33
CD38 P28907 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7619283 0.88 PLA2G2A (0.42) LMNAMEN1KMT2APLA2G2ACYP3A4
SCHEMBL6612458 0.86 PLA2G2A (0.44) PLA2G2AADRA1D
SCHEMBL2590504 0.86 CA5A (0.38) LMNAMEN1KMT2AXBP1PLA2G2A
SCHEMBL6691708 0.80 LMNA (0.48) LMNAMEN1KMT2AXBP1PLA2G2A
SCHEMBL7056324 0.80 ALDH1A1 (0.51) LMNAMEN1KMT2AXBP1PLA2G2A
SCHEMBL7467933 0.80 RPS6KB1 (0.36) MEN1KMT2APLA2G2AALDH1A1MAPK8
SCHEMBL7050801 0.79 PLA2G2A (0.43) LMNAMEN1KMT2APLA2G2ANPSR1
SCHEMBL7420031 0.79 MAPK8 (0.41) LMNAPLA2G2ACYP2C19CYP1A2MAPK8
SCHEMBL7050803 0.79 ADRA1D (0.44) MEN1KMT2APLA2G2AALDH1A1MAPK8
SCHEMBL7417015 0.79 L3MBTL1 (0.43) LMNAKMT2AALDH1A1HTTMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102271507-A Secreted phospholipase A2(SPLA2) Inhibitor and niacin pharmaceutical composition and method for treating cardiovascular diseases and dyslipidemia 2011-12-07 CN disclosed
WO-2011137390-A1 TREATMENT OF MAJOR ADVERSE CARDIAC EVENTS AND ACUTE CORONARY SYNDROME IN DIABETIC PATIENTS USING SECRETORY PHOSPHOLIPASE A2 (SPLA2) INHIBITOR OR SPLA2 INHIBITOR COMBINATION THERAPIES ANTHERA PHARMACEUTICALS, INC. (US) 2011-11-03 WO disclosed
CN-1240210-A Substituted tricyclic compound LILLY CO ELI (US) 2000-01-05 CN disclosed